CLINICAL VARIANTS OF THE COURSE OF HYPER INFLAMMATION SYNDROME IN PATIENTS WITH COVID-19
DOI:
https://doi.org/10.11603/1811-2471.2024.v.i2.14727Keywords:
COVID-19, cytokine storm syndromeAbstract
SUMMARY. The aim – to study the features of the clinical course of COVID-19.
Material and Methods. 270 patients with a severe course of COVID-19, bilateral polysegmental pneumonia took part in a retrospective study. In addition to general clinical tests, the content of ferritin, interleukin-6, D-dimer, fibrinogen, procalcitonin, C-reactive protein were determined in all patients. According to the relevant diagnostic criteria, three groups of patients with different subtypes of cytokine storm syndrome were identified: macrophage activation syndrome, cytokine release syndrome, and sepsis. We tried to evaluate which of the above-mentioned subtypes occurred more often, what are the clinical manifestations of these subtypes.
Results. Macrophage activation syndrome was diagnosed in 8.9 % of those examined, cytokine release syndrome in 81.8 %, and sepsis in 9.3 %. Serum ferritin content in patients with macrophage activation syndrome was significantly higher (p<0.05) compared to those with cytokine release syndrome and compared to the patients with sepsis. Hypofibrinogenemia and pancytopenia were also observed in patients with macrophage release syndrome.
Conclusions. Among the cytokine storm syndromes in patients with COVID-19, the cytokine release syndrome is the most common (81.8 %).
References
Perricone, C., Bartoloni, E., Bursi, R. (2020). COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res., 68(4), 213-224. DOI: 10.1007/s12026-020-09145-5. DOI: https://doi.org/10.1007/s12026-020-09145-5
Henry, B.M., Santos de Oliveira, M.H., Benoit, S. (2020). Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 58(7), 1021-1028. DOI: 10.1515/cclm-2020-0369. DOI: https://doi.org/10.1515/cclm-2020-0369
Gómez-Pastora, J., Weigand, M., Kim, J. (2020). Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? Clin Chim Acta, 509, 249-251. DOI: 10.1016/j.cca. 2020.06.033. Epub 2020 Jun 21. DOI: https://doi.org/10.1016/j.cca.2020.06.033
Zeliha, K.T., Bircan, K., Mervyn, M. COVID-19 and Sepsis. (2021). Turk J Med Sci. 51(SI-1), 3301-3311. DOI: 10.3906/sag-2108-239. DOI: https://doi.org/10.3906/sag-2108-239
Cheney, C. (2020) Severe Covid-19 Illness Is Viral Sepsis. HealthLeaders. Retrieved from: https://www.healthleadersmedia.com/clinical-care/expert-severe-covid-19-illness-viral-sepsis.
Henter, J., Carin Horne, A., Aricó, M. (2007) . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 48(2), 124-31. DOI: 10.1002/pbc.21039. DOI: https://doi.org/10.1002/pbc.21039
Rhodes, A., Evans, L.E., Alhazzani, W. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med., 47(11), 1181-1247. DOI: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2. DOI: https://doi.org/10.1007/s00134-021-06506-y
Peyko, V. (2021). Cytokine Release Syndrome in COVID-19. Int Rev Immunol. 1–14. Published online 2021 Feb 22. DOI: 10.1080/08830185.2021.1884248. DOI: https://doi.org/10.1080/08830185.2021.1884248
Riegler, L.L, Jones, G.P., Lee, D.W. (2019). Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag., 15, 323–335. DOI: 10.2147/TCRM.S150524. DOI: https://doi.org/10.2147/TCRM.S150524
Ruscitti, P., Giacomelli, R. (2020). Ferritin and severe Covid-19, from clinical observations to pathogenic implications and therapeutic perspectives. Isr Med Assoc J., 22(8), 516-518.
McGonagle, D., Sharif, K., O'Regan, A., Bridgewood, C. (2020). The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev, 19(6), 102537. DOI: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3. DOI: https://doi.org/10.1016/j.autrev.2020.102537
Williams, Jr, D.K., Muddiman, D.C. (2009). Absolute quantification of c-reactive protein in human plasma derived from patients with epithelial ovarian cancer utilizing protein cleavage isotope dilution самs spectrometry. J Proteome Res., 8(2), 1085–1090. DOI: 10.1021/pr800922p. DOI: https://doi.org/10.1021/pr800922p
Gosselin, R.C., Owings, J.T., Utter, G.H. (2000). A new method for measuring D-dimer using immunoturbidometry: a study of 255 patients with suspected pulmonary embolism and deep vein thrombosis. Blood Coagul Fibrinolysis., 11(8), 715-21. DOI: 10.1097/00001721-200012000-00004. DOI: https://doi.org/10.1097/00001721-200012000-00004
Juhyun Song, Dae Won Park, Sungwoo Moon. (2019) Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 19(1), 968. DOI: 10.1186/s12879-019-4618-7. DOI: https://doi.org/10.1186/s12879-019-4618-7
Samaee, H., Mohsenzadegan, M., Ala, S. (2020) Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. Int Immunopharmacol., 89(Pt A), 107018. DOI: 10.1016/j.intimp.2020.107018. Epub 2020 Sep 16. DOI: https://doi.org/10.1016/j.intimp.2020.107018
Quah, P., Li, A., Phua, J. (2020). Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care., 24, 285. DOI: 10.1186/s13054-020-03006-1. DOI: https://doi.org/10.1186/s13054-020-03006-1
Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R. (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol., 16, 11, 1446. DOI: 10.3389/fimmu.2020. 01446. eCollection 2020. DOI: https://doi.org/10.3389/fimmu.2020.01446
Shintaro Hojyo, Mona Uchida, Kumiko Tanaka, Rie Hasebe. (2020). How COVID-19 induces cytokine storm with high mortality. Inflamm Regen., 40, 37. DOI: 10.1186/s41232-020-00146-3. eCollection 2020. DOI: https://doi.org/10.1186/s41232-020-00146-3
Colafrancesco, S., Alessandri, C., Conti, F. (2020). COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev., 19(7), 102573. DOI: 10.1016/j.autrev.2020.102573. Epub 2020 May 5. DOI: https://doi.org/10.1016/j.autrev.2020.102573
Dahan, S., Segal, G., Katz, I. (2020). Ferritin as a marker of severity in COVID-19 patients: a fatal correlation. Isr Med Assoc J., 8(22), 429-434. PMID: 32812717.
Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N. (2020) Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe, 27(6), 992-1000.e3. DOI: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21. DOI: https://doi.org/10.1016/j.chom.2020.04.009
Lui, T., Zhang, J., Yang, Y. (2020). The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med., 12(7), e12421. DOI: 10.15252/emmm.202012421. Epub 2020 Jun 5. DOI: https://doi.org/10.15252/emmm.202012421
Ryo Otsuka, Ken-Ichiro Seino. (2020). Macrophage activation syndrome and COVID-19. Inflamm Regen., 40, 19. DOI: 10.1186/s41232-020-00131-w. eCollection 2020. DOI: https://doi.org/10.1186/s41232-020-00131-w
Ruan, Q., Yang, K., Wang, W., Jiang, L., Song. J. (2020). Clinical predictors of mortality due to COVID. Intensive Care Med., 46(5), 846-848. DOI: 10.1007/s00134-020-05991-x. DOI: https://doi.org/10.1007/s00134-020-05991-x
